• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical ophthalmology >Intravitreal injection of tissue plasminogen activator as treatment for an occluded pars plana glaucoma tube
【24h】

Intravitreal injection of tissue plasminogen activator as treatment for an occluded pars plana glaucoma tube

机译：玻璃体腔内注射组织纤溶酶原激活剂治疗闭塞性青光眼管

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Implanting glaucoma tubes through the pars plana in the setting of a corneal transplant is becoming more common, and there are unique problems associated with such a procedure. A 42-year-old man with multiple previous eye surgeries presented with a nonfunctioning pars plana glaucoma tube. There was no view to the tube tip, but it was presumed to be clogged with fibrin. Intravitreal tissue plasminogen activator (tPA) was injected through the pars plana which resulted in intraocular pressure control without further surgery. This new application of intravitreal tPA has not been reported previously. Future research should investigate the optimal effective and safe dose of intravitreal tPA injection to relieve such occlusions.
机译：【摘要】在角膜移植的背景下，将青光眼管通过睫状体平面植入变得越来越普遍，并且这种方法存在一些独特的问题。一位之前有过多次眼科手术的42岁男子出现了无法正常工作的平面青光眼管。管尖端无视野，但推测其被血纤蛋白阻塞。玻璃体组织中的纤溶酶原激活剂（tPA）通过平面注入，无需进一步手术即可控制眼内压。玻璃体内tPA的这种新应用以前尚未见报道。未来的研究应该研究玻璃体内tPA注射以减轻这种阻塞的最佳有效和安全剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号